Boston Scientific Corporation (NYSE:BSX) announces collaboration
Boston Scientific Corporation (NYSE:BSX), primarily engaged in the development, manufacturing and sales of medical devices for use in interventional medical specialties had recently entered into a collaboration with Pelvic Floor Disorders Network. In line with this collaboration, Boston Scientific Corporation (NYSE:BSX) had provided a research and education grant of $1 million to the Pelvic Floor Disorders Network for conducting the clinical trials of SUPeR Study which is aimed at evaluating the effectiveness of two different surgical options for treating women with uterine prolapsed.
Thus by committing itself to the women related treatment therapies, Boston Scientific Corporation (NYSE:BSX) had ascertained its strong commitment for the development of treatment therapies for women healthcare. The Super Study had been planned to enroll around 180 women who are presently considering to undergo surgery for their uterine prolapsed and had thereby planned not to have any more children.
The two surgical options which the enrolled women patients would include the transvaginal mesh repair or the traditional vaginal hysterectomy. The former method of surgery would be conducted using the Boston Scientific Uphold Light Vaginal Support System. The surgical success, side effects, patient safety, cost effectiveness, life quality and body image of the patients would be put to continuous evaluation for a period of six months to five years after the completion of surgery.
Boston Scientific Corporation (NYSE:BSX) had always been focusing on the development and commercialization of intraventional medical devices related to the women healthcare solutions which are aimed at enabling the women to improve their quality of life and regain normalcy health conditions after their pregnancy.
The shares of Boston Scientific Corporation (NYSE:BSX) had recently been declining in the prices owing to weak environmental conditions in the industry. The trading volume of the shares is however at lower levels relative to the average trading volume indicating the shares would regain soon.
The shares of Boston Scientific Corporation (NYSE:BSX) had closed at $9.44 per share on Tuesday, which was a decline of 0.11 percent over the previous close. However, the share prices of the company had touched new 52 week peak levels at $9.61 per share during the intraday price movements.